Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 229   

Articles published

SNY 48.87 -1.54 (-3.05%)
price chart
Sanofi (SNY) Stock: One Big Bet on Diabetes Drugs
Sanofi SA (ADR) (NYSE:SNY) the $130 billion French drug manufacturer, is trying desperately to maintain its position as a leader in diabetes drugs.
Sanofi SA (ADR) Diabetes Drug Toujeo Gets FDA Green Signal  Bidness ETC
Sanofi SA (ADR) (NYSE:SNY) can sell Lantus: approved by US  Investor Wired
Sanofi SA (ADR) New CEO To Focus On US Market
Sanofi's quest to find a replacement for ousted CEO Chris Viehbacher has come to an end. It finally announced Thursday the appointment of Olivier Brandicourt, head of Bayer AG's (ADR)(OTCMKTS:BAYRY) healthcare business, as its new CEO.
Stocks Red-Hot After News: Sanofi SA (ADR) (NYSE:SNY), Vale SA (ADR ...  Investor Wired (press release)
Bayer's Brandicourt To Be Named Sanofi SA (ADR) CEO - Reports
Sanofi SA (ADR) (NYSE:SNY) has been searching for a candidate to replace its ousted Chief Executive Officer Chris Viehbacher ever since October last year; Olivier Brandicourt, head of Bayer AG (ADR)'s (OTCMKTS:BAYRY) healthcare business, might put ...
Zacks Long Term Rating Update on Sanofi SA (ADR)
As much as 5 analysts have advised buy on Sanofi SA (ADR) (NYSE:SNY) with an average broker rating of 2.2. Zacks research analysts are highly pessimistic on the counter and has given it a short term rating of 5, indicating that it is a Underperform ...
Analyst Rating Update on Sanofi SA (ADR)
Analysts at Zacks have given a short term rating of sell on Sanofi-Aventis Sa (NYSE:SNY) with a rank of 4. The counter has received an average rating of 2.2 from 5 brokerage firms.
Price Target Update on Sanofi SA (ADR)  Markets Bureau
Sanofi SA (ADR) (SNY) Launches Inhaled Insulin Afrezza
Sanofi SA (ADR) (NYSE:SNY) has launched its inhalable insulin Afrezza in the US, the company announced before the US markets opened for trading Tuesday.
Company Shares of Sanofi SA (ADR) Rally 1.38%
The short ratio of Sanofi SA (ADR) (NYSE:SNY) is 1.42. On a monthly basis, the short interest has registered a change of 93.1%.
Sanofi SA (SNY) Q4 Earnings Preview
Sanofi SA (ADR) (NYSE:SNY) is scheduled to announce its financial results for the fourth quarter of fiscal year 2014 (4QFY14) on Thursday, February 5 before the market opens.
Zacks Rating Disclosure on Sanofi SA (ADR)  Wall Street Pulse
Shares of Sanofi SA (ADR) Sinks by -1.69% for the Week  Winston View
Sanofi SA (ADR) Analyst Rating Update
Research firm Zacks has rated Sanofi SA (ADR) (NYSE:SNY) and has ranked it at 5, indicating that its shares are a Underperform.
Sanofi SA (ADR) Price Target Update  Bar and Graph Report
Share Price of Sanofi SA (ADR) Rally 2.85%  Winston View
Sanofi SA (ADR) (NYSE:SNY) Ties Up With Voyager For $845M Gene Therapy
Genzyme, a subsidiary of Sanofi SA (ADR) (NYSE:SNY), is partnering with upstart Voyager Therapeutics, which focuses on gene therapy development.